Joel Ackerman - 30 Oct 2025 Form 4 Insider Report for CHAMPIONS ONCOLOGY, INC. (CSBR)

Reporting relationship: Director
Issuer ticker: CSBR
Reported as of: 30 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Nov 2025, 11:19:39 UTC
Prior SEC filing: 18 Mar 2025
Next SEC filing: 07 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Joel Ackerman

Key filing fact

Joel Ackerman filed Form 4 for CHAMPIONS ONCOLOGY, INC. (CSBR) on 06 Nov 2025.

Key facts

This page summarizes Joel Ackerman's Form 4 filing for CHAMPIONS ONCOLOGY, INC. (CSBR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Nov 2025, 11:19.

Change

Previous filing in this sequence was filed on 18 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001220630 Primary reporting owner

ACKERMAN JOEL

Relationship: Director
Address: C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307, HACKENSACK
Signature: /s/ Joel Ackerman
Signature date: 30 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CSBR transaction

Common Stock

Options Exercise

Transaction value: $198,250
Shares: +94,405
Change %: +9.8%
Price: $2.10
Shares after: 1,056,539
Date: 30 Oct 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CSBR transaction Derivative

Option to purchase Common Stock

Options Exercise

Transaction value: $198,250
Shares: -94,405
Change %: -100%
Price: $2.10
Shares after: 0
Date: 30 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 94,405
Exercise price: $2.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

70,804 options were immediately exercisable on grant date of July 19, 2016, with the remaining options vesting and available to exercise on October 31, 2016.